undamentalytics Newsletter
Sign in

Evommune, Inc. balance sheet

At the end of fiscal 2025, Evommune, Inc. had total assets of $225m, total liabilities of $19.4m and shareholders' equity of $206m. It held $44.1m in cash against $0 of debt: net cash of $44.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents164460
Total current assets74153204
Total assets76225302
Accounts payable885
Deferred revenue (current)3——
Total current liabilities281817
Total debt000
Total liabilities291924
Shareholders' equity−144206278
Non-controlling interests and other (assets − liabilities − equity)192——
Net debt (negative = net cash)−16−44−60
Shares outstanding6m—36m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRBU vs EVMNEVMN vs IRDEVMN vs RLAY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evommune, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evommune, Inc.